Clinton Yam, M.D., M.S.
Department of Breast Medical Oncology, Division of Cancer Medicine
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2019 | The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA, MS, Cancer Biology |
| 2008 | National University of Singapore, Singapore, Southeast Asia, MBBS, Medicine and Surgery |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Medical Oncology and Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2014-2016 | Clinical Residency, Internal Medicine, University of Pennsylvania, Philadelphia, PA |
| 2013-2014 | Clinical Internship, Internal Medicine, University of Pennsylvania, Philadelphia, PA |
| 2011-2013 | Clinical Residency, Internal Medicine, National University Hospital Singapore, Singapore |
| 2009-2011 | Medical Officer, Naval Medicine, Republic of Singapore Navy, Singapore |
| 2008-2009 | Clinical Internship, Internal Medicine, National University Hospital, Singapore |
Board Certifications
| 2016 | American Board of Internal Medicine |
| 2014 | United States Medical Licensing Examination |
| 2012 | United States Medical Licensing Examination |
| 2011 | United States Medical Licensing Examination |
| 2011 | United States Medical Licensing Examination |
Experience & Service
Academic Appointments
Fellow, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Clinical Resident, Division of Medicine, University of Pennsylvania, Philadelphia,, PA, 2014 - 2016
Clinical Intern, Division of Medicine, University of Pennsylvania, Philadelphia, PA, 2013 - 2014
Clinical Resident, Division of Medicine, National University Hospital, Singapore, 2011 - 2013
Medical Officer, Naval Medicine Republic of Singapore Navy, Singapore, 2009 - 2011
Clinical Intern, Division of Medicine, National University Hospital, Singapore, 2008 - 2009
Research Scholar, Department of Surgery, University of California San Diego, San Diego, CA, 2007 - 2008
Other Appointments/Responsibilities
Member, American Society of Clinical Oncology National Trainee Council, Houston, TX, 2016 - 2019
Military or Other Governmental Service
Medical Officer, Naval Medicine, Republic of Singapore Navy , 05/2009-11/2011, 2009 - 2011
Selected Publications
Peer-Reviewed Articles
- Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2020. PMID: 32984932.
- Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
- Yam C, Griffiths SM, Yeoh EK. What helps and hinders doctors in engaging in continuous professional development? An explanatory sequential design. PLoS One 15(8):e0237632, 2020. e-Pub 2020. PMID: 32817679.
- Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-51, 2019. e-Pub 2019. PMID: 30610588.
- Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res 9(3):608-18, 2019. e-Pub 2019. PMID: 30949414.
- Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-Kit or PDGFR-β. Invest New Drugs 36(6):1103-9, 2018. e-Pub 2018. PMID: 30311036.
- Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong DS, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced metaplastic and non-metaplastic triple-negative breast cancer. Oncologist 23(11):1300-9, 2018. e-Pub 2018. PMID: 30139837.
- Boddu P, Oviedo SP, Rausch CR, Yam C, Daver N, Kantarjian H, Kadia TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 9(6):1486-9, 2018. e-Pub 2017. PMID: 28958191.
- Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
- Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors. Clin Cancer Res 24(1):22-32, 2018. e-Pub 2017. PMID: 29051322.
- Dai SC, Goldberg D, Agarwal A, Ma GK, Yam C, Ahmad NA, Ginsberg GG, Jaffe DL, Kochman ML, Olthoff KM, Chandrasekhara V. Endoscopic therapy is effective for recurrent anastomotic biliary strictures after orthotopic liver transplantation. Ann Hepatol 16(6):924-31, 2017. PMID: 29055929.
- Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. Am J Hematol 91(9):883-7. e-Pub 2016. PMID: 27197602.
- Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, Loren AW, Frey NV, Stadtmauer EA, Porter DL, Schuster SJ, Nasta SD. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol 91(7):672-6, 2016. e-Pub 2016. PMID: 27012928.
- Yam C, Hristov AC, Schulick RD. Solitary fibrous tumor of the rectosigmoid wall: report of a case and review of the literature. Ann Acad Med Singapore 40(4):192-4, 2011. PMID: 21678005.
- Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, Bouvet M, Hoffman RM. Monotherapy with a tumor-targeting mutant of S typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 164(2):248-55, 2010. e-Pub 2009. PMID: 19766244.
Invited Articles
- Yam C, Mani SA, Moulder SL. Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field. Oncologist 22(9):1086-93, 2017. e-Pub 2017. PMID: 28559413.
Editorials
- Yam C, Hung MC, Hortobagyi GN. CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget 9(76):34193-95, 2018. PMID: 30344934.
Abstracts
- Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. San Antonio Breast Cancer Symposium 2018, 2018.
- Yam C, Seth S, Hess KR, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Chang JT, Moulder SL. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy in metaplastic breast cancer. European Society of Medical Oncology Congress, 2018.
- Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. American Society of Clinical Oncology Annual Meeting (ASCO) 2018, 2018.
- Yam C, Duncan A, Chang JT, Gilcrease MZ, Shah VV, Barton M, Moulder SL. A TRIM24-like mutational signature predicts worse relapse-free survival (RFS) and overall survival (OS) in patients (pts) with metaplastic breast cancer (MpBC). American Association for Cancer Research Annual Meeting 2018, 2018.
- Yam C, Gutierrez Barrera AM, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing. San Antonio Breast Cancer Symposium 2017, 2017.
- Yam C, Huo L, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans W, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. San Antonio Breast Cancer Symposium 2017, 2017.
- Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans W, Moulder SL, Yang WT. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. San Antonio Breast Cancer Symposium 2017, 2017.
- Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch G, Adrada B, Symmans WF, Moulder SL. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). American Society of Clinical Oncology Annual Meeting (ASCO) 2017, 2017.
- Yam C, Crisalli L, Luger S, Loren A, Hexner EO, Frey N, Mangan J, Gao A, Stadtmauer EA, Porter D, Reshef R. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity conditioned allogeneic stem-cell transplantation. American Society of Hematology Annual Meeting (ASH) 2015, 2015.
- Yam C, Landsburg DJ, Lin X, Mato A, Svoboda J, Loren A, Frey N, Stadtmauer EA, Porter D, Schuster SJ, Nasta SD. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with ALK-negative peripheral T cell lymphoma. American Society of Hematology Annual Meeting (ASH) 2015, 2015.
- Yam C, Stopfer J, Brandt A, Powers J, Long JM, Maxwell KN, Bradbury AR, Nathanson KL, Domchek SM. Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer. American Society of Clinical Oncology Annual Meeting (ASCO) 2015, 2015.
- Dai S, Yam C, Agarwal A, Goldberg DS, Jaffe DL, Kochman ML, Chandrasekhara V. Recurrence of liver transplant-related biliary anastomotic strictures after successful endoscopic therapy. Digestive Disease Week (DDW) 2014, 2014.
- Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, Bouvet M, Hoffman RM. Targeting a modified Salmonella typhimurium strain to pancreatic-cancer liver metastasis. American Association for Cancer Research Annual Meeting (AACR) 2008, 2008.
- Zhao M, Yam C, Hayashi K, Kaushal S, McElroy M, Bouvet M, Hoffman RM. Human patient colon cancer growth is inhibited by a genetically modified S. typhimurium in nude mice. American Association for Cancer Research Annual Meeting (AACR) 2008, 2008.
- Zhao M, Yoram B, Ma H, Yam C, Li S, Matin A, Hoffman RM. Efficacy of chemotherapy enhanced by targeted bacterial delivery of a prodrug-converting enzyme to a human colon tumor in nude mice. American Association for Cancer Research Annual Meeting (AACR) 2008, 2008.
Book Chapters
- Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL. Innovative strategies: Targeting subtypes in metastatic breast cancer. In: Am Soc Clin Oncol Educ Book. 38, 65-77, 2018.
Grant & Contract Support
| Title: | Gianni Bonadonna Breast Cancer Research Fellowship |
| Funding Source: | Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Young Investigator Award |
| Funding Source: | Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Phase II Study-Anti-PD-1 with HT inpts with HR + IBC who did not achieve a pCR to neo adjuvant |
| Funding Source: | Merk |
| Role: | Principal Investigator |
| Title: | Neoadjuvant treatment response monitoring of breast cancer with molecular photoacoustic imaging |
| Funding Source: | CPRIT |
| Role: | Investigator |
| Title: | The microbiota-immune axis and response to neoadjuvant chemo(immuno)therapy in triple-negative breast cancer |
| Funding Source: | Conquer Cancer Foundation |
| Role: | Principal Investigator |
| Title: | A Phase II Study of Neoadjuvant Anti-PD-L1 (MPDL3280A) Therapy in Combination with Nab-Paclitaxel in Triple Negative Breast Cancer (TNBC) |
| Funding Source: | Genetech Inc |
| Role: | Principal Investigator |
| Title: | Delineating the evolution and ecology of chemoresistance in breast cancer with single cell genomics |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Title: | BC210331: Role of DKK3 in Triple Negative Breast Cancer Tumor Progression and Resistance to Therapy |
| Funding Source: | DoD |
| Role: | Investigator |
| Title: | Phase II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC) |
| Funding Source: | Methodist flow thru NIH |
| Role: | Investigator |
| Title: | STRATEGIC Alliance Agreement |
| Funding Source: | BostonGene |
| Role: | Investigator |
| Title: | Validation of a novel 3D culture platform for TNBC treatment selection |
| Funding Source: | Methodist |
| Role: | Investigator |
Patient Reviews
CV information above last modified March 20, 2024